To investigate the secretion of progesterone (P4) and corticosteroid binding globulin (CBG) by granulosa luteal cells (GC) as well as the mRNA levels of CBG and 3β hydroxisteroid dehydrogenase (3β HSD), in women with and without endometriosis in vivo and in vitro. Methods: Prospective study in a private, university-affiliated assisted reproduction unit, including women with severe endometriosis (n = 14) or without the disease (n = 20) undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer. GC were obtained from each follicle aspirated, pooled for each patient, and follicular and blood contaminating leukocytes depleted through immunomagnetic purification. Secreted P4 and CBG, and mRNA for both 3β HSD and CBG were determined in vivo and in vitro using RIA and reverse transcription followed by competitive polymerase chain reaction (cRT-PCR).
INTRODUCTION
Endometriosis is a mysterious disease that consists in the presence of endometrial tissue implanted out of the uterine cavity. Innumerable studies have attempted to explain the causes of the subfertile status that endometriosis-affected women suffer, but without a distortion of the anatomical tract, the reasons are unclear, and many hypotheses have been raised (1) .
The application of in vitro fertilization (IVF) permitted a closer analysis of phenomena that otherwise were occult such as fertilization, foliculogenesis, early embryo development, or implantation. Based on previous data from our Institution (2,3), we hypothesized that there is decreased pregnancy and implantation rates in women with endometriosis compared to controls, and that the presence of endometriomas in women receiving oocytes from young healthy donors was not different in terms of pregnancy rates, compared with those recipients without the disease (4) . This is a clear sign of low quality oocytes, may be caused by a detrimental background in the cases of endometriosis that could potentially affect the quality of the resulting embryo; it has also been demonstrated to be worse in these women (5, 6) .
Our clinical findings were further studied addressing the characteristics of the endocrine intrafollicular milieu in these patients analyzing granulosa cell function in short-term cultures and follicular fluid (FF) (7) for steroids. Promising results were obtained, showing an increase in the secretion of progesterone (P4) by granulosa cell cultures in women with endometriosis, whereas no differences were found in estradiol, testosterone, and androstenedione.
Thus, the endocrine microenvironment within the follicles needed further investigation, since the causes of these P4 concentrations within the follicle are unclear. Many factors can affect intrafollicular P4 concentration, and among them, those related with its production or transport are serious candidates to be implicated.
Pregnenolone is converted in P4 in the human ovaries by the granulosa luteal cells (GC). The enzyme responsible for its biosynthesis in the human gonads is 3β hydroxisteroid dehydrogenase (3β HSD) Type II, in a two-step reaction, transforming first an hydroxyl group into ketone, and second, transferring the double bond to the position 4-5, from the position 5-6 in the molecule (8) .
Otherwise, one of the molecules implicated in P4 bioavailability is the corticosteroid binding globulin (CBG), which is also expressed in the GC and present in FF. Moreover, a high concentration of this molecule within the follicles has been correlated with success in the IVF cycles (9) . An increase in the expression of these molecules can be directly related with an increase in the intrafollicular progesterone, thus suggesting endocrinological defects in these patients.
Our aim in this study was to ascertain these molecules in women with endometriosis, compared with those without the disease, in vivo (analyzing the granulosa cells that have been conditioned by other follicular cells immediately after purification, and the follicular fluids), and in vitro (with 24-h cell cultures after purification, to analyze granulosa cell function itself).
MATERIALS AND METHODS
Luteinized GC and FF were obtained from a total of 34 women undergoing oocyte retrieval for IVF at the Instituto Valenciano de Infertilidad from December 1999 to December 2000. All patients have undergone laparoscopy for a period not greater than 1 year before the IVF cycle, and were grouped according to the findings (10) as healthy (n = 14) or having severe endometriosis (n = 20) because of the presence of ovarian endometriomas that were still present after laparoscopy (all of them stage III-IV). The Institutional Review Board of our clinic approved the project, and written consent was obtained from each patient.
The protocol for ovarian stimulation was started by pituitary desensitization with daily subcutaneous administration of 1 mg leuprolide acetate (Procrin, Abbott S.A., Madrid, Spain) and began in the luteal phase of the menstrual cycle. Serum E 2 levels <60 pg/mL (220 pmol/L) and negative vaginal ultrasonographic scans were used to define ovarian quiescence. Days 1 and 2 of ovarian stimulation, two ampoules/day hMG (hMG Lepori, Farma-Lepori, Madrid, Spain) were administered together with two ampoules of high purity FSH (Neo-Fertinorm, Serono Laboratories, Madrid, Spain). Days 3, 4, and 5 of ovarian stimulation, one ampoule/day hMG plus one ampoule/day FSH were administered to each patient. Beginning Day 6, hMG and FSH were administered on an individual basis according to serum E 2 and transvaginal ovarian ultrasound scans. The criteria for hCG administration (10,000 IU, Profasi, Serono Laboratories, Madrid, Spain) were the presence of two or more follicles >1.9 cm in greatest diameter, and serum E 2 levels >800 pg/mL (2940 pmol/L). Leuprolide acetate, FSH, and hMG injections were discontinued the day of hCG administration. Oocyte retrieval was scheduled 36 h after hCG injection. The luteal phase was supported with vaginal administration of micronized P (400 mg/day, Progeffik, Laboratorios Effik, Madrid, Spain).
Granulosa Cells and Follicular Fluid Preparation
FFs without obvious blood contamination from individual patients were centrifuged, supernatants pooled, and stored at −20
• C until the radioimmunoasay (RIA) was performed.
Follicular cells from all follicles greater than 16 mm in individual patients were pooled (total number of follicles included in this study was 154), and contaminating blood cells were eliminated using both salt treatment method (11), and immunobead treatment, using mouse monoclonal antihuman CD14 and mouse monoclonal antihuman CD45 (Sigma, St. Louis, MO), and then with specific secondary sheep antimouse IgG antibodies, coupled with magnetic beads (Dynal, Oslo, Norway). After incubation, bead-bound cells were removed. Isolated GC were >99% pure as assessed by flow cytometry analysis (data not shown).
GC Cultures
GC were plated triplicate at a density of 2.5 × 10 5 viable cells per well (assessed by Trypan Blue staining, Sigma, St. Louis, MO), in 36-mm diameter culture dishes (Falcon, Beckton-Dickinson, NJ) with 1 mL M-199 medium (Sigma, St. Louis, MO), supplemented with 1% fetal bovine serum (FBS, Gibco, Life Technologies, Glasgow, Scotland), gentamicin 50 µg/mL of medium (Gibco, Life Technologies, Glasgow, Scotland), and fungizone, 250 ng/mL of medium (Gibco, Life Technologies, Glasgow, Scotland), for 24 h at 37
• C, 5% CO 2 . Once cells adhered, media were discarded to remove nonadherent cells, and wells were washed twice with M-199, and cultured for 24 h in the media above described. Subsequently, the conditioned culture media were stored at −20
• C until RIA assays and cells were detached from plastic with the use of RNAstat 60 reagent (Tel-Test, Friendswood, TX) for RNA purification.
RNA Extraction
The RNA extraction was performed from both freshly isolated and cultured GC, according to the Chomczynski and Sacchi (12) method, and quantified by spectrophotometry on a Shimadzu 1201 (Izasa, Madrid, Spain) spectrophotometer.
Reverse Transcription (RT)
RT was carried out using Adventage RT-for-PCR KIT (Clontech, Palo Alto, CA). Mastermix per sample was prepared as follows: 4 µL of 5X reaction buffer, 1 µL of dNTP mix (10 mM each), 0.5 µL of Recombinant RNAse Inhibitor, 1 µL of MMLV (Moloney-Murine Leukemia Virus) reverse transcriptase. One µg of each sample was diluted to a final volume of 12.5 µL in diethylpyrocarbonate (DEPC) treated water; and then 1 µL of oligo (dT) 18 was added, heated at 70
• C, 2 min, and kept on ice until mastermix (6.5 µL) was added. Once all components were mixed, the reaction was incubated at 42
• C for 1 h, and heated at 94
• C for 5 min to stop cDNA synthesis and destroy DNAse activity. The product was diluted to a final volume of 100 µL with DEPC treated water and stored at −20
• C until the PCR.
Primers for PCR
Sequences for the mRNAs to be detected in human GC were obtained from the GenBank Database of the National Center for Biotechnology Information (NCBI) of the National Institute of Health (NIH, Internet Address: http://www2.ncbi.nlm.nih.gov/cgibin/genbank). Each set of primer sequences was designed by using the program OLIGO 5.0 Primer Analysis Software (National Bioscience, Plymouth, MN) and synthesized by GIBCO-BRL Custom Primers (Gibco, Life Technologies, Glasgow, Scotland). Design was performed to cross intron/exon boundaries to ensure that amplified products were from cDNAs and not from contaminating genomic DNA. Primer locations on cDNA, sizes of amplified fragments, and sequences are listed in Table I .
Construction of Competitive Fragments
Floating primers for 3β HSD, CBG, and β-actin were designed from the sequence of cDNA between the 3 and 5 binding sites followed by the reverse complementary 3 -binding site. RT products from isolated GC were amplified in 35 cycles of PCR with the use of an Eppendorf Mastercycler personal (Eppendorf, Hamburg, Germany); the products were resolved by 1% agarose gel electrophoresis, stained with ethidium bromide (EtBr), and extracted from the gel with the Sephaglass TM Band Prep Kit (Pharmacia Biotech, Cambridge, UK). The concentration was quantified by spectrophotometry. Resulting products had a deletion between 3 and 5 primer binding sites, compared with the target cDNA to be detected. PCR products were confirmed by independent sequence analysis. Sequences of all primers, and data on fragment sizes are described in Table I .
cPCR
Volumes of RT products (Table II) were mixed with PCR mastermix containing 5 µL 10X buffer, 2.5 µL 50 mM MgCl 2 , 0.5 µL Taq Polymerase (all Table I (Table II) , and sterile distilled water were added to a final volume of 50 µL. These volumes of competitor cDNAs to be added in the cPCR experiments were decided after previous cPCRs fixing the amount of sample target cDNAs and adding serial dilutions of competitor, and were chosen with the aim of keeping the ratios of competitor versus target cDNAs within 0.5 and 1.5 in as much samples as possible. The cPCR reactions were carried out using an Eppendorf Personal Mastercycler (Eppendorf, Hamburg, Germany), with the following program using a heated lid (100 • C): first heated to 94
• C, 5 min, following n cycles of 94 • C, 45 s; T • C (Table II) , 45 s; 72
• C, 45 s, with a final extension of 72
• C, 5 min, and cooled down to 4 • C. Products were then electrophoresed in a 1% agarose gel in the presence of EtBr, and bands analyzed in an image analysis system (Gelprinter Plus, TDI, Madrid, Spain), using the 1D Software (TDI, Madrid, Spain). Each cPCR experiment was performed a minimum of 2-3 times with very similar results. In the negative controls, an equal volume of sterile distilled water substituted competitor and target.
All the results of the expression analysis were normalized with previous β-actin cPCR results.
Radioimmunoasay (RIA)
P4 and CBG concentrations in FF and conditioned GC media were determined in duplicate by RIA with the use of a commercially available kit (ICN Biomedicals, Costa Mesa, CA) and following manufacturer's instructions.
Statistical Analysis
Data were expressed as mean ± standard deviation (SD). Student's t test was carried out between groups, since data were normally distributed. Significance was defined as p < 0.05. The statistical analysis was performed using the Statistical Package for Social Sciences 9.0 (SPSS, Chicago, IL).
RESULTS
The presence of specific mRNAs for 3β HSD and CBG molecules was detected in all samples together with control β-actin.
The analysis of the expression of mRNA for 3β HSD in GC did not reveal any difference when patients with and without endometriosis were compared in the cPCR experiments (Fig. 1) . In vivo 3β HSD expression in endometriosis patients was 1.2 ± 0.5 while in women without the disease it was 1.0 ± 0.1, both expressed as ratios between amplification of target versus competitor molecules. In the in vitro experiments, the expression of 3β HSD was 0.6 ± 0.3 in the endometriosis group and 0.7 ± 0.1 in the control group, indicating that GC express this mRNA in the same manner.
The cPCR results on mRNA expression for CBG (Fig. 2) did not reveal any difference when patients with endometriosis were compared with healthy patients. The ratios of the optical densities of target versus competitor in vivo were 1.3 ± 0.6 in those patients with the disease and 1.2 ± 0.3 in healthy women. In the cultured GC from patients with endometriosis, the expression of CBG was 0.7 ± 0.1, while in women without endometriosis the ratio was 0.8 ± 0.3.
Both secreted CBG and P4 were detected in all GC culture supernatants and in every FF analyzed. Secreted CBG levels in vivo and in vitro, for endometriosis and control group, were comparable (Table III) , as measured by RIA, hence reinforcing (Table III) .
DISCUSSION
In this study we wanted to find an explanation to preceding studies with controversial results regarding the intrafollicular presence of P4 in women with endometriosis as compared with healthy controls and their implications in the pathophysiology of endometriosis.
The past results yielded by our research line on this topic demonstrated that there was an increase in the GC secretion of P4 in short-term cultures, and also in its presence in the FF of women with edometriosis compared with nonendometriosis patients, that could be involved in the clinical results of our IVF and ovum donation program (7) .
Moreover, in another related study by Harlow et al. (13) , trying to give rationale to the reduced fertilization that they found in women with endometriosis (14) as the cause of endometriosis-associated infertility, they found, together with an aromatase dysfunction, that the ability to secrete progesterone in the GC from these women was diminished as compared to controls, again in vitro in cell cultures of 3 h. Nevertheless, their population included tubal damage or unexplained infertility as controls (with absence of endometriosis confirmed by laparoscopy in all of them), and infertile couples with treated or untreated edometriosis. Measurements were done by fluoroimmunoassay, but no determination of leukocytes in the cultures or in vivo experiments was attempted.
Other studies by Skrzypczak (15) also found an impairment in the progesterone production of GC from women with severe ovarian endometriosis, as in the actual work we did, compared with healthy women, but low number of patients (only 11) were included in the study.
These initial data together suggested an impairment of the follicular function that could convey to subtle alteration of the oocytes, mediated by the altered presence of P4 inside the follicle, although they were contradictory.
This work aimed to explore the secretion of two molecules, CBG and P4, as well as the mRNA expression of the CBG and of the enzyme that catalyses the ovarian formation of P4 (3β HSD Type II), in the GC of women with endometriosis in comparison to patients without the disease in experiments in vivo and in vitro. Thus, the present results are in discordance with them, since no differences in P4 were found in a very similar design, and the molecules related to P4 biology studied were synthesized in a similar way.
Herein we took special care in avoiding the presence of leukocytes (both from inside the follicle and contaminating blood) by purification and subsequent analysis of GCs for their presence within the FF. These cells are able to modulate steroidogenesis (16, 17) , and they have been demonstrated to be approximately 15% of the cells present in the FF without peripheral blood contamination (18) , and near to 60% in contaminated FF (author's own unpublished data). In addition, we only pooled for the in vivo determinations in both groups, those FF coming from the early follicles, before blood contamination was evident, because of inherent follicular puncture limitations. P4 amounts in peripheral blood could mask the real situation in the follicle, thus interfering with the results, if this step is not carefully performed. We firmly believe that GC model of study, applied to any research field, is a useful tool but also requires these previous steps to be completely sure of its reliability and reproducibility.
Moreover, the statistical power of the study because of the sample size, and the fact that we only included patients with a laparoscopy performed less than 1 year before the ovum pickup, indicating the absence or presence of endometriosis (in the latter, with ovarian endometriomas), adds strength to our results.
It is difficult to give rationale to the different results that counteract what has been formerly reported in the literature on the measurement of P4. In this study, the use of adequate controls was included, the results in vivo and in vitro were correlated, and two molecules implicated in the concentrations of P4 inside the follicles had been determined with the analysis of gene expression and of the secreted molecule, ensuring a more complete approximation to the situation.
Nevertheless, we must consider that active implants behave differently than inactive disease, and we did not discriminate among them. Perhaps the selection of patients should include a parallel evaluation of the degree of activation of the disease to compare results, since the disease could display different degrees of activation (19, 20) .
Other problems within the GC including defects in the apoptosis pathway (21, 22) , in diverse paracrine factors (23) , and even intrafollicular leukocytes (24) have been described and could explain a different status within the follicle, but recent studies compared to the present one again gave conflicting results (25) . Anyhow, the available literature is insufficient, and efforts are needed to ascertain which factors or processes are really implicated in the infertility-related aspects of the disease in the molecular dimension. But, before this is done, a standardization of the design of any basic study on this complicated topic is needed; this is necessary to make results comparable and so that a consensus may be reached, paving the way for determinant advances in this field.
